IMS Health, Danbury, Conn., announced the purchase of DecisionView, a San Francisco-based developer of software that tracks patient enrollment in clinical trials.
Financial terms of the deal weren't disclosed. DecisionView has gathered data from more than 1,200 clinical trials in more than 90 countries, according to IMS Health's news release. Officials from IMS Health, a Healthcare Technology Holdings subsidiary, say the acquisition will give clinical-trial sponsors and research groups access to better data in making patient enrollment choices and trial site selections. DecisionView will become part of IMS' Healthcare Value Solutions business.
"Today, the clinical-trial planning and enrollment process is inefficient due to the lack of real-world data and analytics in trials management and decisionmaking," said Andrew Kress, senior vice president of IMS Healthcare Value Solutions, in the release. "Approximately 90% of clinical trials don't finish on time, with trial enrollment cited as the leading cause of the delays. Through this acquisition, we will enhance clinical trial productivity—transforming the way patient studies are planned and executed."